TRPC6 and hypertrophic cardiomyopathy: It has been shown that the maximum reduction of LV function has been associated with the following SNPs in those patients treated with trastuzumab: LDB2 (limb domain binding 2), BRINP1 (BMP/retinoic acid inducible neural-specific protein 1, a suppressor of cell cycle progression), RAB22A (a member of the RAS oncogene family which is key in endocytic trafficking), TRPC6 (transient receptor potential cation channel subfamily C member 6, involved in cardiac remodelling and hypertrophic cardiomyopathy), LINC01060 (a long intergenic noncoding RNA) and chromosome 6 intergenic region.